… therapies for COVID-19 have been developed, highlighting our limited understanding of the
pathogenesis of COVID-19. … mainly on the pathophysiology of COVID-19-associated ARDS. …

… of SARS-CoV-2 in December 2019 has brought the world to a standstill. While less pathogenic
than the 2002–2003 SARS-CoV… to SARS-CoV has helped to determine pathogenesis and …

… in vivo therapeutic efficacy of oral GS-621763 in a mouse model of SARS-CoV-2 pathogenesis.
… , we show that GS-621763 therapy provides similar levels of protection from SARS-CoV-…

… Meanwhile, some clinical trials evaluated the therapeutic effect of glucocorticoids and found
that they can significantly reduce the cytokine storm and relieve the corresponding tissue …

… The timing of treatment initiation and treatment efficacy were varied. Darker colors indicate
a larger reduction in the viral load AUC. The parameter setting used for the simulation in (A–C…

… plays a key role in viral pathogenesis, evolutions, and transmission. The … SARS-CoV-2 S
protein, its essential role in pathogenesis, and its use in the development of potential therapies …

… This review provides a concise summary of relevant literature on the pathogenesis and
treatment of SARS-CoV-2. Information on this topic is changing rapidly, but the authors believe …

… SARS-CoV-2. The present study highlights the genomic, proteomic, pathogenesis, and
therapeutic strategies in SARS-CoV-2 … in SARS-CoV-2 and, compared them with SARS-CoV and …

… Baricitinib is a clinically approved JAK inhibitor that exhibits a therapeutic effect against
SARS-CoV-2 infection in the rhesus macaque model. Baricitinib-treated animals showed …

… In conclusion, the current treatment of COVID-19 patients with severe type and critical type
is the key to controlling the rising number of deaths. We recommend early initiation of IVIg and …